Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| UNITED THERAPEUTICS CorpUTHR · Entity 664 | EVP & GENERAL COUNSEL | October 01, 2026 | October 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
UNITED THERAPEUTICS Corp
Report date October 01, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 45,172 |
Ending reported balance
After 2026-10-01 transaction · row 11
11 source rows · reconciled sequenceRow 1 · 2026-10-01 · Exercise / conversion · Acquired 8,300 · Balance 53,472 F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. Row 2 · 2026-10-01 · Sale · Disposed 880 · Balance 52,592 F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F2: This transaction was executed in multiple trades at prices ranging from $558.30 to $558.31. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 3 · 2026-10-01 · Sale · Disposed 1,480 · Balance 51,112 F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F3: This transaction was executed in multiple trades at prices ranging from $560.00 to $560.50. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 4 · 2026-10-01 · Sale · Disposed 780 · Balance 50,332 F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F4: This transaction was executed in multiple trades at prices ranging from $561.70 to $562.27. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 5 · 2026-10-01 · Sale · Disposed 1,480 · Balance 48,852 F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F5: This transaction was executed in multiple trades at prices ranging from $562.80 to $563.43. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 6 · 2026-10-01 · Sale · Disposed 400 · Balance 48,452 F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F6: This transaction was executed in multiple trades at prices ranging from $566.405 to $566.41. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 7 · 2026-10-01 · Sale · Disposed 720 · Balance 47,732 F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F7: This transaction was executed in multiple trades at prices ranging from $567.495 to $568.175. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 8 · 2026-10-01 · Sale · Disposed 739 · Balance 46,993 F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F8: This transaction was executed in multiple trades at prices ranging from $568.94 to $569.79. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 9 · 2026-10-01 · Sale · Disposed 838 · Balance 46,155 F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F9: This transaction was executed in multiple trades at prices ranging from $570.405 to $571.32. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 10 · 2026-10-01 · Sale · Disposed 823 · Balance 45,332 F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F10: This transaction was executed in multiple trades at prices ranging from $571.48 to $572.45. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 11 · 2026-10-01 · Sale · Disposed 160 · Balance 45,172 F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $146.03 · Expires 2027-03-15 | Direct | 39,240 |
Reported balance
After 2026-10-01 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-10-01 · Exercise / conversion · Disposed 8,300 · Balance 39,240 F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025.
F2: This transaction was executed in multiple trades at prices ranging from $558.30 to $558.31. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3: This transaction was executed in multiple trades at prices ranging from $560.00 to $560.50. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4: This transaction was executed in multiple trades at prices ranging from $561.70 to $562.27. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5: This transaction was executed in multiple trades at prices ranging from $562.80 to $563.43. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F6: This transaction was executed in multiple trades at prices ranging from $566.405 to $566.41. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F7: This transaction was executed in multiple trades at prices ranging from $567.495 to $568.175. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F8: This transaction was executed in multiple trades at prices ranging from $568.94 to $569.79. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F9: This transaction was executed in multiple trades at prices ranging from $570.405 to $571.32. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F10: This transaction was executed in multiple trades at prices ranging from $571.48 to $572.45. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 04, 2023 Filed May 4, 2023 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,480 | $215.84 | $319,445.27 |
DisclosureSEC source: 0001415889-23-007302 · form4-05042023_040502.xml · nonDerivative · entry 3 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,834 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $215.605 to $216.58. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 04, 2023 Filed May 4, 2023 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 3,285 | $215.15 | $706,759.21 |
DisclosureSEC source: 0001415889-23-007302 · form4-05042023_040502.xml · nonDerivative · entry 2 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,314 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $214.565 to $215.55. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 04, 2023 Filed May 4, 2023 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 6,000 | $120.26 | $721,560.00 |
DisclosureSEC source: 0001415889-23-007302 · form4-05042023_040502.xml · nonDerivative · entry 1 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,599 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| April 20, 2023 Filed Apr 20, 2023 21:00 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 6,000 | $0.00 Strike: $120.26 | $0.00 |
DisclosureSEC source: 0001415889-23-006773 · form4-04202023_090421.xml · derivative · entry 5 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,500 Underlying: Common Stock · 6,000 shares Expires 2026-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| April 20, 2023 Filed Apr 20, 2023 21:00 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 900 | $225.22 | $202,695.03 |
DisclosureSEC source: 0001415889-23-006773 · form4-04202023_090421.xml · nonDerivative · entry 4 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,599 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F4 · price: This transaction was executed in multiple trades at prices ranging from $225.17 to $225.72. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 20, 2023 Filed Apr 20, 2023 21:00 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 701 | $224.41 | $157,308.05 |
DisclosureSEC source: 0001415889-23-006773 · form4-04202023_090421.xml · nonDerivative · entry 3 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,499 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $224.07 to $224.86. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 20, 2023 Filed Apr 20, 2023 21:00 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 4,399 | $223.63 | $983,751.45 |
DisclosureSEC source: 0001415889-23-006773 · form4-04202023_090421.xml · nonDerivative · entry 2 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,200 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $223.06 to $223.86. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 20, 2023 Filed Apr 20, 2023 21:00 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 6,000 | $120.26 | $721,560.00 |
DisclosureSEC source: 0001415889-23-006773 · form4-04202023_090421.xml · nonDerivative · entry 1 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,599 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| April 06, 2023 Filed Apr 7, 2023 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 6,000 | $0.00 Strike: $120.26 | $0.00 |
DisclosureSEC source: 0001415889-23-006358 · form4-04072023_040404.xml · derivative · entry 5 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,500 Underlying: Common Stock · 6,000 shares Expires 2026-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| April 06, 2023 Filed Apr 7, 2023 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 500 | $233.66 | $116,830.00 |
DisclosureSEC source: 0001415889-23-006358 · form4-04072023_040404.xml · nonDerivative · entry 4 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,599 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| April 06, 2023 Filed Apr 7, 2023 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 4,531 | $232.88 | $1,055,189.25 |
DisclosureSEC source: 0001415889-23-006358 · form4-04072023_040404.xml · nonDerivative · entry 3 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,099 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $232.48 to $233.34. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 06, 2023 Filed Apr 7, 2023 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 969 | $231.93 | $224,735.71 |
DisclosureSEC source: 0001415889-23-006358 · form4-04072023_040404.xml · nonDerivative · entry 2 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,630 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $231.46 to $232.43. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 06, 2023 Filed Apr 7, 2023 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 6,000 | $120.26 | $721,560.00 |
DisclosureSEC source: 0001415889-23-006358 · form4-04072023_040404.xml · nonDerivative · entry 1 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,599 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| March 16, 2023 Filed Mar 17, 2023 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 6,000 | $0.00 Strike: $120.26 | $0.00 |
DisclosureSEC source: 0001415889-23-005120 · form4-03172023_040301.xml · derivative · entry 7 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,500 Underlying: Common Stock · 6,000 shares Expires 2026-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| March 16, 2023 Filed Mar 17, 2023 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 200 | $216.09 | $43,217.70 |
DisclosureSEC source: 0001415889-23-005120 · form4-03172023_040301.xml · nonDerivative · entry 6 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,599 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F7 · price: This transaction was executed in multiple trades at prices ranging from $216.06 to $216.09. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 16, 2023 Filed Mar 17, 2023 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,526 | $215.40 | $328,697.50 |
DisclosureSEC source: 0001415889-23-005120 · form4-03172023_040301.xml · nonDerivative · entry 5 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,799 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F6 · price: This transaction was executed in multiple trades at prices ranging from $215.02 to $215.695. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 16, 2023 Filed Mar 17, 2023 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 2,522 | $214.52 | $541,007.33 |
DisclosureSEC source: 0001415889-23-005120 · form4-03172023_040301.xml · nonDerivative · entry 4 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,325 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F5 · price: This transaction was executed in multiple trades at prices ranging from $214.00 to $214.99. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 16, 2023 Filed Mar 17, 2023 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,277 | $213.61 | $272,783.42 |
DisclosureSEC source: 0001415889-23-005120 · form4-03172023_040301.xml · nonDerivative · entry 3 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,847 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F4 · price: This transaction was executed in multiple trades at prices ranging from $212.98 to $213.88. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 16, 2023 Filed Mar 17, 2023 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 475 | $211.87 | $100,636.49 |
DisclosureSEC source: 0001415889-23-005120 · form4-03172023_040301.xml · nonDerivative · entry 2 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,124 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $211.80 to $212.255. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 16, 2023 Filed Mar 17, 2023 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 6,000 | $120.26 | $721,560.00 |
DisclosureSEC source: 0001415889-23-005120 · form4-03172023_040301.xml · nonDerivative · entry 1 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,599 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F2 · balance_after: Includes 112 shares acquired on March 3, 2023, under the United Therapeutics Corporation Employee Stock Purchase Plan. Read SEC document |
| March 15, 2023 Filed Feb 26, 2026 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantRestricted Stock Units · Derivative | 8,895 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001231589-26-000005 · primarydocument.xml · derivative · entry 3 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,895 Underlying: Common Stock · 8,895 shares Expires not disclosed F5 · security: These performance-based restricted stock units were initially awarded on March 15, 2023, subject to a three-year performance condition tied to clinical development performance during 2023-2025, which was determined on January 20, 2026. The number of restricted stock units reported represents the number of restricted stock units earned based on performance, all of which will vest on March 15, 2026. F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F4 · derivative.expiration_date: Not applicable as restricted stock units do not have an expiration date. Read SEC document |
| March 15, 2023 Filed Feb 26, 2026 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantRestricted Stock Units · Derivative | 7,796 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001231589-26-000005 · primarydocument.xml · derivative · entry 2 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,796 Underlying: Common Stock · 7,796 shares Expires not disclosed F2 · security: These performance-based restricted stock units were initially awarded on March 15, 2023, subject to a three-year performance condition tied to average revenue growth during 2023-2025, which was determined on February 25, 2026. The number of restricted stock units reported represents the number of restricted stock units earned based on performance, all of which will vest on March 15, 2026. F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F4 · derivative.expiration_date: Not applicable as restricted stock units do not have an expiration date. Read SEC document |
| March 15, 2023 Filed Feb 26, 2026 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantStock Options · Derivative | 49,860 | $0.00 Strike: $217.50 | $0.00 |
DisclosureSEC source: 0001231589-26-000005 · primarydocument.xml · derivative · entry 1 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,860 Underlying: Common Stock · 49,860 shares Expires 2033-03-15 F1 · security: These performance-based stock options were initially awarded on March 15, 2023, subject to a three-year performance condition tied to average cash profit margin during 2023-2025, which was determined on February 25, 2026. The number of stock options reported represents the number of options earned based on performance, all of which will vest on March 15, 2026. Read SEC document |
| March 02, 2023 Filed Mar 2, 2023 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 6,000 | $0.00 Strike: $120.26 | $0.00 |
DisclosureSEC source: 0001415889-23-003825 · form4-03022023_040343.xml · derivative · entry 6 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,500 Underlying: Common Stock · 6,000 shares Expires 2026-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| March 02, 2023 Filed Mar 2, 2023 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 471 | $244.39 | $115,106.94 |
DisclosureSEC source: 0001415889-23-003825 · form4-03022023_040343.xml · nonDerivative · entry 5 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,397 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F5 · price: This transaction was executed in multiple trades at prices ranging from $244.03 to $244.42. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 02, 2023 Filed Mar 2, 2023 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 703 | $243.24 | $170,998.99 |
DisclosureSEC source: 0001415889-23-003825 · form4-03022023_040343.xml · nonDerivative · entry 4 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,868 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F4 · price: This transaction was executed in multiple trades at prices ranging from $242.98 to $243.88. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 02, 2023 Filed Mar 2, 2023 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 4,226 | $242.45 | $1,024,608.49 |
DisclosureSEC source: 0001415889-23-003825 · form4-03022023_040343.xml · nonDerivative · entry 3 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,571 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $241.98 to $242.92. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 02, 2023 Filed Mar 2, 2023 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 600 | $241.17 | $144,703.20 |
DisclosureSEC source: 0001415889-23-003825 · form4-03022023_040343.xml · nonDerivative · entry 2 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,797 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $240.97 to $241.36. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 02, 2023 Filed Mar 2, 2023 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 6,000 | $120.26 | $721,560.00 |
DisclosureSEC source: 0001415889-23-003825 · form4-03022023_040343.xml · nonDerivative · entry 1 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,397 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| February 16, 2023 Filed Feb 16, 2023 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 6,000 | $0.00 Strike: $120.26 | $0.00 |
DisclosureSEC source: 0001415889-23-002697 · form4-02162023_040201.xml · derivative · entry 7 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,500 Underlying: Common Stock · 6,000 shares Expires 2026-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| February 16, 2023 Filed Feb 16, 2023 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 100 | $253.79 | $25,378.50 |
DisclosureSEC source: 0001415889-23-002697 · form4-02162023_040201.xml · nonDerivative · entry 6 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,397 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| February 16, 2023 Filed Feb 16, 2023 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 100 | $252.00 | $25,200.00 |
DisclosureSEC source: 0001415889-23-002697 · form4-02162023_040201.xml · nonDerivative · entry 5 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,497 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| February 16, 2023 Filed Feb 16, 2023 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 400 | $250.88 | $100,350.00 |
DisclosureSEC source: 0001415889-23-002697 · form4-02162023_040201.xml · nonDerivative · entry 4 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,597 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F4 · price: This transaction was executed in multiple trades at prices ranging from $250.41 to $251.03. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 16, 2023 Filed Feb 16, 2023 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,216 | $249.65 | $303,571.97 |
DisclosureSEC source: 0001415889-23-002697 · form4-02162023_040201.xml · nonDerivative · entry 3 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,997 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $249.33 to $250.00. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 16, 2023 Filed Feb 16, 2023 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 4,184 | $248.67 | $1,040,421.05 |
DisclosureSEC source: 0001415889-23-002697 · form4-02162023_040201.xml · nonDerivative · entry 2 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,213 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $248.27 to $249.22. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 16, 2023 Filed Feb 16, 2023 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 6,000 | $120.26 | $721,560.00 |
DisclosureSEC source: 0001415889-23-002697 · form4-02162023_040201.xml · nonDerivative · entry 1 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,397 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| February 02, 2023 Filed Feb 2, 2023 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 6,000 | $0.00 Strike: $120.26 | $0.00 |
DisclosureSEC source: 0001415889-23-001810 · form4-02022023_040207.xml · derivative · entry 5 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 6,000 shares Expires 2026-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| February 02, 2023 Filed Feb 2, 2023 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 200 | $258.99 | $51,798.00 |
DisclosureSEC source: 0001415889-23-001810 · form4-02022023_040207.xml · nonDerivative · entry 4 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,397 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| February 02, 2023 Filed Feb 2, 2023 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,400 | $255.46 | $357,641.48 |
DisclosureSEC source: 0001415889-23-001810 · form4-02022023_040207.xml · nonDerivative · entry 3 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,597 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $255.04 to $255.975. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 02, 2023 Filed Feb 2, 2023 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 4,400 | $254.17 | $1,118,354.16 |
DisclosureSEC source: 0001415889-23-001810 · form4-02022023_040207.xml · nonDerivative · entry 2 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,997 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $253.77 to $254.76. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 02, 2023 Filed Feb 2, 2023 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 6,000 | $120.26 | $721,560.00 |
DisclosureSEC source: 0001415889-23-001810 · form4-02022023_040207.xml · nonDerivative · entry 1 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,397 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| January 19, 2023 Filed Jan 19, 2023 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 6,000 | $0.00 Strike: $120.26 | $0.00 |
DisclosureSEC source: 0001415889-23-001206 · form4-01192023_040102.xml · derivative · entry 5 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,500 Underlying: Common Stock · 6,000 shares Expires 2026-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| January 19, 2023 Filed Jan 19, 2023 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 300 | $259.96 | $77,987.58 |
DisclosureSEC source: 0001415889-23-001206 · form4-01192023_040102.xml · nonDerivative · entry 4 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,397 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F4 · price: This transaction was executed in multiple trades at prices ranging from $259.86 to $260.075. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 19, 2023 Filed Jan 19, 2023 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 4,500 | $259.02 | $1,165,594.50 |
DisclosureSEC source: 0001415889-23-001206 · form4-01192023_040102.xml · nonDerivative · entry 3 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,697 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $258.73 to $259.64. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 19, 2023 Filed Jan 19, 2023 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,200 | $258.42 | $310,101.12 |
DisclosureSEC source: 0001415889-23-001206 · form4-01192023_040102.xml · nonDerivative · entry 2 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,197 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $257.72 to $258.70. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 19, 2023 Filed Jan 19, 2023 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 6,000 | $120.26 | $721,560.00 |
DisclosureSEC source: 0001415889-23-001206 · form4-01192023_040102.xml · nonDerivative · entry 1 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,397 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| January 05, 2023 Filed Jan 5, 2023 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 6,000 | $0.00 Strike: $120.26 | $0.00 |
DisclosureSEC source: 0001415889-23-000549 · form4-01052023_040110.xml · derivative · entry 5 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,500 Underlying: Common Stock · 6,000 shares Expires 2026-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| January 05, 2023 Filed Jan 5, 2023 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 704 | $274.76 | $193,430.34 |
DisclosureSEC source: 0001415889-23-000549 · form4-01052023_040110.xml · nonDerivative · entry 4 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,397 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F4 · price: This transaction was executed in multiple trades at prices ranging from $274.62 to $274.86. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 05, 2023 Filed Jan 5, 2023 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 3,096 | $274.13 | $848,707.41 |
DisclosureSEC source: 0001415889-23-000549 · form4-01052023_040110.xml · nonDerivative · entry 3 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,101 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $273.485 to $274.46. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 05, 2023 Filed Jan 5, 2023 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 2,200 | $273.08 | $600,777.10 |
DisclosureSEC source: 0001415889-23-000549 · form4-01052023_040110.xml · nonDerivative · entry 2 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,197 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $272.40 to $273.39. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.